CytoDyn $CYDY mit Blockbuster Potential WKN: A0YHA5 (Seite 60)
eröffnet am 04.04.19 22:54:12 von
neuester Beitrag 29.11.23 15:46:05 von
neuester Beitrag 29.11.23 15:46:05 von
Beiträge: 30.091
ID: 1.301.376
ID: 1.301.376
Aufrufe heute: 0
Gesamt: 3.060.206
Gesamt: 3.060.206
Aktive User: 0
ISIN: US23283M1018 · WKN: A0YHA5 · Symbol: CYDY
0,1580
EUR
+6,76 %
+0,0100 EUR
Letzter Kurs 28.03.24 Stuttgart
Neuigkeiten
11.07.23 · globenewswire |
24.05.23 · globenewswire |
05.04.23 · globenewswire |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
3,0700 | +88,34 | |
1,0800 | +69,01 | |
4,9000 | +44,12 | |
5,0000 | +43,68 | |
0,9500 | +34,94 |
Wertpapier | Kurs | Perf. % |
---|---|---|
1,8300 | -18,30 | |
2,1000 | -18,92 | |
5,2600 | -29,40 | |
2,0400 | -35,44 | |
3,5100 | -46,00 |
Beitrag zu dieser Diskussion schreiben
Antwort auf Beitrag Nr.: 69.369.230 von Malecon am 19.09.21 18:17:09Sali sehe deine komentare in mehreren forums und finde sie recht intressant was denkst du wie hoch wird der kurs 3$ 5 $ ?
CytoDyn gibt Beilegung des Bundesrechtsstreits mit Rosenbaum/Patterson Activist Group bekannt
https://www.cytodyn.com/newsroom/press-releases/detail/558/c…
https://www.cytodyn.com/newsroom/press-releases/detail/558/c…
Antwort auf Beitrag Nr.: 69.377.108 von yelw0rc am 20.09.21 16:16:01
„Das Auto ist eine vorübergehende Erscheinung, ich glaube an das Pferd“.
„Das Smartphone wird sich niemals am Markt etablieren“.
„…wer hier investiert, dem ist wahrlich kaum noch zu helfen“.
JMHO
Zitat von yelw0rc: https://www.fda.gov/drugs/drug-safety-and-availability/state…
With the conclusion of both the CD10 and CD12 clinical trials, it has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19. In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints. The primary endpoint for the CD10 trial relied on a measure of participants’ COVID-19 symptoms called a “total clinical symptom score”, which was assigned based on the severity of each participant’s fever, muscle aches, shortness of breath, and cough. This score ranged from 0 (no symptoms) to 12 (all 4 symptoms present and severe). The CD10 trial results showed no clinically meaningful differences in average change in “total clinical symptom score” from baseline to Day 14 between study arms (-3.5 in the leronlimab group versus -3.4 in the placebo group). Additionally, none of the secondary endpoints were met in this study, including mortality, time to symptom resolution, and time to return to normal activity. Taken together, the CD10 results indicate that most study participants experienced resolution in COVID-19 symptoms regardless of whether they received leronlimab or placebo.
wer hier noch investiert, dem ist wahrlich kaum noch zu helfen
„Das Auto ist eine vorübergehende Erscheinung, ich glaube an das Pferd“.
„Das Smartphone wird sich niemals am Markt etablieren“.
„…wer hier investiert, dem ist wahrlich kaum noch zu helfen“.
JMHO
Antwort auf Beitrag Nr.: 69.377.108 von yelw0rc am 20.09.21 16:16:01Gratulliere, du wärmst einen Post von vor 4 Monaten auf 👏
Antwort auf Beitrag Nr.: 69.376.880 von Cytopro am 20.09.21 15:59:40https://www.fda.gov/drugs/drug-safety-and-availability/state…
With the conclusion of both the CD10 and CD12 clinical trials, it has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19. In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints. The primary endpoint for the CD10 trial relied on a measure of participants’ COVID-19 symptoms called a “total clinical symptom score”, which was assigned based on the severity of each participant’s fever, muscle aches, shortness of breath, and cough. This score ranged from 0 (no symptoms) to 12 (all 4 symptoms present and severe). The CD10 trial results showed no clinically meaningful differences in average change in “total clinical symptom score” from baseline to Day 14 between study arms (-3.5 in the leronlimab group versus -3.4 in the placebo group). Additionally, none of the secondary endpoints were met in this study, including mortality, time to symptom resolution, and time to return to normal activity. Taken together, the CD10 results indicate that most study participants experienced resolution in COVID-19 symptoms regardless of whether they received leronlimab or placebo.
wer hier noch investiert, dem ist wahrlich kaum noch zu helfen
With the conclusion of both the CD10 and CD12 clinical trials, it has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19. In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints. The primary endpoint for the CD10 trial relied on a measure of participants’ COVID-19 symptoms called a “total clinical symptom score”, which was assigned based on the severity of each participant’s fever, muscle aches, shortness of breath, and cough. This score ranged from 0 (no symptoms) to 12 (all 4 symptoms present and severe). The CD10 trial results showed no clinically meaningful differences in average change in “total clinical symptom score” from baseline to Day 14 between study arms (-3.5 in the leronlimab group versus -3.4 in the placebo group). Additionally, none of the secondary endpoints were met in this study, including mortality, time to symptom resolution, and time to return to normal activity. Taken together, the CD10 results indicate that most study participants experienced resolution in COVID-19 symptoms regardless of whether they received leronlimab or placebo.
wer hier noch investiert, dem ist wahrlich kaum noch zu helfen
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: unnötige Provokation, bleiben Sie bitte sachlich, persönliche Angriffe bitte unterlassen
Hier auch endlich mal wieder aktualisiert:
Recent Data
Fee Available Updated
12.3 % 1,000 2021-09-20 09:45:03
12.3 % 10,000 2021-09-20 09:30:03
10.0 % 7,000 2021-09-16 16:45:03
😜
Recent Data
Fee Available Updated
12.3 % 1,000 2021-09-20 09:45:03
12.3 % 10,000 2021-09-20 09:30:03
10.0 % 7,000 2021-09-16 16:45:03
😜
Antwort auf Beitrag Nr.: 69.376.820 von Discoveryy am 20.09.21 15:54:12
Ups... sorry, Quelle: https://www.cnbc.com/quotes/CYDY
Zitat von Discoveryy: Last | 9:52 AM EDT
2.16
quote price arrow up+0.15 (+7.46%)
Volume
1,265,721
📈 ... die 2$ scheinen nun überrannt... 😜 (entgegen dem Trend...)
Ups... sorry, Quelle: https://www.cnbc.com/quotes/CYDY
Last | 9:52 AM EDT
2.16
quote price arrow up+0.15 (+7.46%)
Volume
1,265,721
📈 ... die 2$ scheinen nun überrannt... 😜 (entgegen dem Trend...)
2.16
quote price arrow up+0.15 (+7.46%)
Volume
1,265,721
📈 ... die 2$ scheinen nun überrannt... 😜 (entgegen dem Trend...)
CytoDyn $CYDY mit Blockbuster Potential WKN: A0YHA5